**Table S1. Median (5th, 95th percentiles) dose-normalized Cmin (ng/mL per mg dose) in patients of different age ranges**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Patient** | **CYP3A4/PgP inducer** |  | **1 to < 3 years** | **≥ 3 to < 6 years** | **≥ 6 to < 12 years** | **≥ 12 to < 18 years** | **≥ 18 years** |
| TSC-seizure | No | Median  N, n | 2.01 (0.9-4)  9, 51 | 1.57 (0.6-3.2)  39, 222 | 1.09 (0.4-3)  61, 432 | 0.87 (0.3-2.3)  45, 341 | 0.9 (0.3-3.4)  36, 291 |
| TSC-seizure | Yes | Median  N, n | 1.04 (0.5-3.7)  14, 52 | 0.88 (0.4-1.8)  58, 375 | 0.73 (0.3-1.9)  77, 583 | 0.48 (0.2-1.4)  59, 440 | 0.48 (0.2-1.1)  40, 278 |

N represents number of patients, n represents number of samples.

CYP3A4 = cytochrome P450 3A4; Cmin = predose everolimus concentration; PgP = phosphoglycoprotein; TSC = tuberous sclerosis complex.

**Table S2. Adverse event profile by treatment arm**

|  |  |  |  |
| --- | --- | --- | --- |
| **Adverse event, %** | **Placebo  (n = 119)** | **Everolimus  3-7 ng/mL  (n = 117)** | **Everolimus  9-15 ng/mL  (n = 130)** |
| **Any AE** | 77.3 | 92.3 | 94.6 |
| **Grade 3 and 4 AEs** | 10.9 | 17.9 | 23.8 |
| **Suspected grade 3 and 4 AEs** | 5.9 | 13.7 | 14.6 |
| **Serious AEs** | 2.5 | 13.7 | 13.8 |
| **Suspected serious AEs** | 0.8 | 8.5 | 8.5 |

AE = adverse event.